Compare EQH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQH | CYTK |
|---|---|---|
| Founded | 1859 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 10.7B |
| IPO Year | 2017 | 2004 |
| Metric | EQH | CYTK |
|---|---|---|
| Price | $49.36 | $71.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $56.82 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 2.6M | 1.9M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $11,665,000,000.00 | $13,368,000.00 |
| Revenue This Year | $43.13 | $7.37 |
| Revenue Next Year | $7.45 | $310.19 |
| P/E Ratio | $100.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.20 | $47.22 |
| 52 Week High | $55.15 | $88.31 |
| Indicator | EQH | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 38.45 |
| Support Level | $47.10 | $59.19 |
| Resistance Level | $49.39 | $79.66 |
| Average True Range (ATR) | 1.10 | 2.17 |
| MACD | -0.26 | -0.45 |
| Stochastic Oscillator | 16.81 | 26.41 |
Equitable Holdings Inc is a financial services company providing retirement, asset management, and wealth management solutions for individual and institutional clients, operating through three segments. The Retirement segment generates the majority of revenue and offers annuities, retirement savings plans, institutional savings products, and includes the spread lending business. The Asset Management segment provides diversified investment management and related services globally through Institutional, Retail, and Private Wealth channels and reflects the business of AB. The Wealth Management segment offers advisory accounts, financial planning and advice, life insurance, and annuity products. Revenues are earned predominantly from fee income, income from investments, and insurance premiums.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.